RapidEye
- After analyzing the Phase 3 data of the drug Multikine in the treatment of head and neck cancer, CEL-SCI’s stock on NYSE surged by 40% in morning trading on Friday.
- The company revealed that Multikine managed to reduce the five-year risk of death by 50% as per the results of the study.
- “The bias analysis demonstrated that the survival benefit truly stems from Multikine rather than any imbalance in the patient cohorts,” stated Geert Kersten, the CEO of CEL-SCI. “We are excited to unveil the preliminary outcomes as we gear up to present the data to regulatory bodies before our forthcoming confirmatory registration study.”
